This article is more than 5 years old. Information may no longer be current.

Real-world study: CyPass with phaco reduces IOP, medications

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOS ANGELES — Both number of medications and IOP remained reduced at 3 years in a European study of the Alcon CyPass micro-stent combined with cataract surgery, according to a speaker giving results of the CyCLE study.

The CyCLE was a registry study in the European Union designed to evaluate the long-term safety and surgical outcomes of the CyPass micro-stent in real-world clinical practice followed for 3 years.

Magda Rau

“The 3-year safety profile of the supraciliary micro-stent gives long-term evidence of its compatibility with cataract surgery and the potential to implant the micro-stent earlier in the glaucoma treatment as compared with conventional filtration glaucoma surgery,” Magda Rau, MD, said at the American Society of Cataract and Refractive Surgery meeting.

Patients enrolled in the study were “all comers,” with refractory or non-refractory cases of primary or secondary open-angle glaucoma.

Of 245 eyes undergoing phacoemulsification combined with the CyPass, for the 93 eyes with uncontrolled baseline IOP of 21 mm Hg or higher, the therapeutic goal was to lower IOP. Of the remaining 152 eyes with controlled baseline IOP less than 21 mm Hg, the therapeutic goal was to reduce the number of medications.

In eyes with uncontrolled baseline IOP, the micro-stent reduced IOP from baseline by 28% to 34% through the 3-year follow-up period. Additionally, the proportion of eyes controlled with no medication increased from 8% at baseline to 19% at month 36.

In eyes with controlled baseline IOP, the micro-stent maintained IOP at constant levels and reduced the medication use from 2 to 1.1 through 3 years. Additionally, 45% of eyes used no medication at month 36 compared with 3% at baseline. – by Patricia Nale, ELS

Reference:

Rau M. Results from the CyCLE study for supraciliary microstent implantation combined with cataract surgery for open-angle glaucoma. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 5-9, 2017; Los Angeles.

Disclosure: Rau reports no relevant financial disclosures.